바로가기 및 건너띄기 링크
본문 바로가기
주메뉴 바로가기

뉴스레터

home > 자료실> 뉴스레터

글자크기

CJ files suit to allow generic Viagra-Issue 4 (Nov. 2011)

CJ files suit to allow generic Viagra-Issue 4 (Nov. 2011) : 작성자, 작성일, 조회수, 정보 제공
작성자 관리자
작성일 2011-11-01 조회수 5,437
media
media

Issue 4 (Nov. 2011)

Views 482 Votes 0 2011.11.04 23:12:30
bg.jpg
htlogo_01.jpg
htlogo_02.jpg
Issue 4 (Nov. 2011)
htlogo_04.jpg
HT Korea News
line.jpg
1st Annual Korea-US HT Partnerships in NYC
1st Annual Korea-US HT Partnerships in NYC
The conference of '1st Annual Korea-US HT Partnerships' was held on October 27th, 28th (Thur, Fri) of 2011 at Marriot Marquis(9th Floor) Hotel in New York City. KHIDI USA and KOTRA hosted this event, and it was sponsored by Korean Ministry of ....more
S. Korea free trade agreement -- a win for medical device companies?
S. Korea free trade agreement -- a win for medical device companies?
A free trade agreement with South Korea passed yesterday by the U.S. Congress could boost medical device exports to one of the industry's biggest markets, manufacturers say. The agreement, which still has to be ratified by the Korean government, was one of three long-simmering trade pacts ...more
CJ files suit to allow generic Viagra
CJ files suit to allow generic Viagra
Food and pharmaceutical company CJ CheilJedang on Wednesday filed a nullity suit against Pfizer over the "use" patent of impotence medicine Viagra. "This is the first lawsuit filed to nullify the patent of Viagra in Korea. Other drug companies that are preparing for the generic forms are also keeping a very close watch on it," a...more
Hallyu stars boost food brand sales in Korea
Hallyu stars boost food brand sales in Korea
VIPS, a local steakhouse chain owned by CJ Foodville, has seen a 30 percent increase in its sales since singer/actor Rain became a commercial model for the company in July. "Many of the new customers are Rain's fans from China and ...more
Yonsei to diagnose patients in Russia
Yonsei to diagnose patients in Russia
Yonsei University will export its IT-based medical equipment and services to Russia's Sakhalin island that will enable remote diagnostics of Russian patients by university professors and doctors here, the Ministry of Knowledge Economy said...more
[Meet the CEO] Sungho CEO sees R&D as a core competence
[Meet the CEO] Sungho CEO sees R&D as a core competence
Park Hwan-woo, president and CEO of KOSDAQ-listed Sungho Electronics Co. (www.sungho.net) was quick to use a metaphor in explaining what the company's core business is. And his metaphor of choice is a human heart. Not that Sungho is making an artificial heart. The company's specialty is producing ...more
Hyundai Heavy, Asan Medical team up for hospital robotics
Hyundai Heavy, Asan Medical team up for hospital robotics
Hyundai Heavy Industries Co. and Asan Medical Center will collaborate in developing medical robots and equipment. The agreement to collaborate in the field was signed in Seoul on Monday. "Medical robots are essential for providing the best...more
SKT, SNU Hospital join hands for health care
SKT, SNU Hospital join hands for health care
SK Telecom, the country's largest mobile carrier, said Tuesday that the company and Seoul National University Hospital recently agreed to establish a joint venture involving health care. The new joint venture is expected to lead the future health care ...more
Columbus Pioneers News
line.jpg
INFINITT Healthcare
line_01.jpg
Everland-Samsung Elec to Invest W90b in Biologics
INFINITT Healthcare to Develop the World's First 'Integrated Radiation Therapy Management System'
INFINITT Healthcare has launched a new project in collaboration with the Radiation Oncology department of Samsung Medical Center for the development of the world's first integrated radiation therapy management system. Total funding for the.... more
ViroMed
line_01.jpg
ViroMed Takes One Step Closer to Finding a Cure for Diabetic Neuropathy through US Clinical Trial I/II
ViroMed Takes One Step Closer to Finding a Cure for Diabetic Neuropathy through US Clinical Trial I/II
ViroMed Co., Ltd. (KOSDAQ: 084990) today announced that the results of the Phase I/II study on its diabetic neuropathy therapeutic drug (VM202-DPN) were presented at 'BIO KOREA 2011 Conference & Exhibition' held at COEX (Seoul, Korea) from...more
ViroMed Takes One Step Closer to Finding a Cure for Diabetic Neuropathy through US Clinical Trial I/II
ViroMed's DNA Medicine(VM202) Receives Phase II Approval for PAD in China
VM202-PAD Phase II trials are currently being conducted in Korea and the US, and the Chinese FDA approval will give ViroMed a jump-start to initiate a Phase II trial of the same design in China as well. This means there is now a greater ...more
Medipost
line_01.jpg
MEDI-FUTURE, Inc., Starts First Sales of
Medipost aims to dominate global biopharmaceutical industry
In the early 2000s, Korea was basking in the biotechnology boom thanks largely to advanced stem cell research. Strong government support led many research centers to open up bio-related facilities including cord blood banks....more
AMOREPACIFIC
line_01.jpg
AMOREPACIFIC Strives for study on 'Salvia miltiorrhiza bunge (S. Miltiorrhiza)', A Rare Medicinal Plant
AMOREPACIFIC Strives for study on 'Salvia miltiorrhiza bunge (S. Miltiorrhiza)', A Rare Medicinal Plant
AMOREPACIFIC (President and CEO, Kyung-Bae Suh) will conclude MOU for the 'Development of cosmetic ingredients and products through the study of rare medicinal plants, S. Miltiorrhiza' with Yangyang-gun at Youngyang county....more
A cosmetics pioneer
A cosmetics pioneer
Amore Pacific, Korea's largest cosmetics company, has been a pioneer in the Korean cosmetics industry. It was the first company in Korea to establish cosmetics research and development centers in 1954....more
AmorePacific eyes gain in China market share
AmorePacific eyes gain in China market share
HONG KONG (Yonhap News) - AmorePacific Corp., South Korea's No. 1 cosmetics manufacturer, will likely see its share of the Chinese market rise this year from a year ago, company officials said Tuesday. The market share is expected to ...more
Korea Health Industry Development Institute USA Office,
420 Lexington Ave., Suite 2546, New York, NY 10170
T. 646.783.6090 F.646.783.6099
Email : info@khidiusa.org If you are no longer interested you can unsubscribe instantly
logo_01.jpg logo_02.jpg

댓글등록

로그인 또는 본인확인 후 작성 가능합니다.

0/250

의견입력영역